Briacell Therap (NASDAQ:BCTX) Stock Price Down 1.8% – Should You Sell?

Briacell Therap (NASDAQ:BCTX)’s stock price fell 1.8% during trading on Monday . The stock traded as low as $10.80 and last traded at $11.11. 20,404 shares changed hands during trading, a decline of 81% from the average session volume of 105,020 shares. The stock had previously closed at $11.31.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $320.00.

Briacell Therap Price Performance

The stock has a market capitalization of $7.53 million, a P/E ratio of -0.13 and a beta of 1.21. The company’s 50-day simple moving average is $10.73 and its 200-day simple moving average is $19.06.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.